Connect with us
The main European stock markets opened this Wednesday with mixed trends. Specifically, Paris and London lost 0.1% and 0.05%, respectively, while Milan and Frankfurt rose 0.16%...
Grifols' guidance for 2024 estimates recording an adjusted EBITDA of more than 1.8 billion euros, as well as a free cash flow of five million euros....
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition with its star drug. Rovi has...
This counterattack by Gotham comes weeks after Grifols has received accolades following the confirmation of the sale to Haier of its 20% stake in Shanghai Raas...
Grifols explained that the Strategic Alliance and Share Purchase Agreement signed with Haier on December 29th, 2023, is “binding” and that both parties are contractually obliged...
Qube Research & Technologies increases its short position on Grifols to 1.23%, up from 1.19%, amid market volatility due to the conflict with Gotham City Research....
BlackRock increased its stake in Grifols to 4.2% amid the Spanish company's legal dispute with Gotham City Research. The 4.1% rise in Grifols' stock boosted the...
The presentation of the results was scheduled for the end of February, but Grifols wants to move forward so that the situation is not unsustainable for...
The intraday minimum was marked at 10:31 a.m., with 8.22 euros, after the stock spent an hour and a half in a volatility auction trying to...
Grifols is a listed Catalan pharmaceutical company. The company's activity focuses on the research, development, manufacturing, and marketing of products derived from plasma (blood products), intravenous therapy...